



19. Arbeitstagung „Experimentelle Neuroonkologie“
30. April bis 01. Mai 2010
Minden



19. Arbeitstagung „Experimentelle Neuroonkologie“

30. April und 01. Mai 2010

PROGRAMM

Freitag, 30. April 2010

13.30 Uhr: **Begrüßung und Eröffnung**
Erdlenbruch

13.35 - 15.40 Uhr: **Experimentelle Neuroonkologie Teil I (5)**
Vorsitz: Rutkowski / Kramm

- Elke Pfaff¹, Marc Remke^{1,2}, Dominik Sturm¹, Hendrik Witt^{1,2}, André O. von Bueren³, Andrea Wittmann¹, Anna Schöttler¹, Wolfram Scheurlen⁴, Andreas E. Kulozik², Olaf Witt^{2,5}, Andreas von Deimling^{6,7}, Stefan Rutkowski³, Cynthia Hawkins⁸, Uri Tabori⁸, Peter Lichter¹, Andrey Korshunov⁷ and Stefan M. Pfister^{1,2}

¹Division Molecular Genetics, German Cancer Research Center, Heidelberg, Germany; ²Dept. of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Germany; ³Dept. of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁴Cnopf'sche Kinderklinik, Nürnberg, Germany; ⁵Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; ⁶Dept. of Neuropathology, University of Heidelberg, Germany; ⁷Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; ⁸The Hospital for Sick Children, Brain Tumor Research Centre, Toronto, Canada

“Is TP53 mutation status a predictive marker in medulloblastoma?”

- Sabine Häcker¹, Sabine Karl¹, Isabelle Mader¹, Tilmann Schweitzer², Jürgen Krauss², Stefan Rutkowski³, Klaus-Michael Debatin¹, Simone Fulda¹

¹University Children's Hospital, Ulm; ²Dept. of Neurosurgery, Würzburg; ³Dept. of Pediatric Hematology and Oncology, Hamburg, Germany

“Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation”

- Sabrina Pleier^{1,2}, Dominik Sturm¹, Marc Remke^{1,2}, Hendrik Witt^{1,2}, Violaine Goidts^{1,2}, Guido Reifenberger³, Jörg Felsberg³, Andreas Kulozik², Andrey Korshunov⁴, Peter Lichter¹, Stefan M. Pfister^{1,2}

¹Division Molecular Genetics, German Cancer Research Center Heidelberg; ²Dept. of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg; ³Dept. of Neuropathology, Heinrich-Heine-University of Düsseldorf; ⁴Dept. of Neuropathology, University Hospital Heidelberg, Germany

“Role of SGK1 as novel prognostic marker in medulloblastoma”

- A. O. von Bueren^{1,2}, C. Oehler-Jänne³, T. Shalaby², M. Pruschy³, B. Seifert⁴, M. Warmuth-Metz⁵, S. Rutkowski¹, M. A. Grotzer²

¹Dept. of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²Neuro-Oncology Program, University Children's Hospital Zurich, Zurich, Switzerland; ³Dept. of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland;

⁴Biostatistics Unit, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland; ⁵Dept. of Neuroradiology, University of Wuerzburg, Wuerzburg, Germany

"High c-MYC expression sensitizes medulloblastoma cells to DNA damaging agents"

- O. Witt^{1,2}, G. Fleischhack³, M. Remke^{2,8}, T. Milde^{1,2}, S. Rutkowski⁴, T. Pietsch⁶, A.E. Kulozik², A. von Deimling⁵, M.D. Taylor⁷, A. Korshunov⁵, S. Pfister^{2,8}

¹CCU Pediatric Oncology, German Cancer Research Center, Heidelberg; ²Dept. of Pediatric Oncology, University of Heidelberg Medical Center; ³Dept. of Pediatric Oncology, University of Bonn; ⁴Dept. of Pediatric Oncology, University Medical Center Hamburg-Eppendorf; ⁵Dept. of Neuropathology, University of Heidelberg Medical Center; ⁶Dept. of Neuropathology, University of Bonn; ⁷Hospital for Sick Children, Division of Neurosurgery, Toronto, Canada; ⁸Division of Molecular Genetics, German Cancer Research Center

"Molecular characterization and targeted therapy of recurrent medulloblastoma"

15.40 - 16.00 Uhr: Kaffeepause

16.00 - 17.00 Uhr: key not lecture

Paul Workman

"Translation of the paediatric high grade glioma genome"

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SN2 5NG, United Kingdom

17.00 - 17.20 Uhr: Kaffeepause

17.20 - 19.25 Uhr: Experimentelle Neuroonkologie Teil II (5)

Vorsitz: Fulda / Witt

- Sebastian Bender^{1,2}, Hendrik Witt^{1,2}, Andrey Korshunov³, Till Milde^{2,4}, Marina Ryzhova⁵, Andreas E. Kulozik², Peter Lichter¹, Stefan M. Pfister^{1,2}

¹Division Molecular Genetics, German Cancer Research Center Heidelberg, Germany; ²Dept. of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Germany; ³Dept. of Neuropathology, University Hospital Heidelberg, Germany; ⁴Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; ⁵NN Burdenko Neurosurgical Institute, Moscow, Russia

„WDR16 as a novel prognostic biomarker in pediatric ependymoma"

- Biörn Koos¹, Ann-Katrin Koblitz¹, Sonja Mertsch¹, Jörg Felsberg², Rudi Beschorner³, Werner Paulus¹, Martin Hasselblatt¹

¹Institute of Neuropathology, University Hospital Münster; ²Dept. of Neuropathology, Heinrich-Heine University, Düsseldorf; ³Institute of Brain Research, Eberhard-Karls University, Tübingen, Germany

"Ecotropic viral integration site 1 (EVI-1) is over-expressed intracranial ependymomas"

- Hendrik Witt^{1,2}, Sebastian Bender^{1,2}, Axel Benner³, Thomas Hielscher³, Stephanie Riester¹, Marc Remke^{1,2}, Till Milde⁴, Andreas von Deimling⁵, Andreas E. Kulozik², Olaf Witt^{2,4}, Peter Lichter¹, Andrey Korshunov^{5,6} and Stefan M. Pfister^{1,2}

¹Division Molecular Genetics, German Cancer Research Center Heidelberg, Germany; ²Dept. of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg; ³Division Biostatistics, German Cancer Research Center, Heidelberg; ⁴Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg; ⁵Dept. of Neuropathology, University of Heidelberg; ⁶Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany

“Subgroup-specific molecular alterations in intracranial ependymoma might account for marked clinical heterogeneity”

- Ann-Katrin Koblitz, Björn Koos, Werner Paulus, Martin Hasselblatt
Institute for Neuropathology, University Hospital Muenster, Germany

“Activating mutations of the KRAS gene and over-expression of K-Ras are absent in intracranial ependymomas.”

- Georg Karpel-Massler, Christian Rainer Wirtz, Marc-Eric Halatsch
Neurochirurgische Universitätsklinik Ulm, Steinhövelstraße 9, 89075 Ulm

„Identification of two conditional resistance genes for erlotinib in human glioblastoma multiforme cell lines”

20.00 Uhr: Abendessen

Gemeinsame Gesprächsrunde

Samstag, 01. Mai 2010

08.30 – 10.10 Uhr: Experimentelle Neuroonkologie Teil III (4)

Vorsitz: Frühwald / Van Gool

- Dominik Sturm¹, Marc Remke^{1,2}, Hendrik Witt^{1,2}, Guido Reifenberger³, Jörg Felsberg³, Christoph Kramm⁴, Ulrike Rausche⁴, Christian Hartmann⁵, Andreas v. Deimling⁵, Andrey Korshunov⁵, Olaf Witt^{2,6}, Andreas E. Kulozik², Peter Lichter¹, Stefan Pfister^{1,2}

¹Division Molecular Genetics, German Cancer Research Center Heidelberg; ²Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg; ³Department of Neuropathology, Heinrich-Heine-University of Duesseldorf; ⁴Department of Pediatrics and Adolescent Medicine, Martin-Luther-University Halle-Wittenberg; ⁵Department of Neuropathology, University Hospital Heidelberg; ⁶Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center Heidelberg, Germany

"Integrative Genomics Approach identifies Molecular Characteristics of Pediatric Glioblastoma"

- Henning Lünenbürger, Claudia Lanvers-Kaminsky, Michael C. Frühwald*

University Children's Hospital Münster, Dept. of Pediatric Hematology and Oncology

"In vitro Evaluation of novel and standard anti-cancer agents for rhabdoid tumors"

- Jörg Mühlisch¹, Birte Ostermann¹, Heribert Jürgens¹, Michael C. Frühwald¹

¹University Children's Hospital Muenster, Dept. of Pediatric Hematology and Oncology, Germany

"Evaluation of DNA methylation in rhabdoid tumors"

- Huriye Cin¹, Claus Meyer², Hendrik Witt^{1,3}, Marc Remke^{1,3}, Wibke Janzarik^{4,5}, Ton Nu Van Anh⁵, Heike Olbrich^{5,6}, Andreas von Deimling^{7,8}, Andreas E. Kulozik³, Rolf Marschalek², Olaf Witt⁹, Heymut Omran^{5,6}, Peter Lichter¹, Andrey Korshunov⁸, Stefan Pfister^{1,3}

¹Division Molecular Genetics, German Cancer Research Center Heidelberg; ²Institute of Pharmaceutical Biology, Diagnostic Center of Acute Leukemia (DCAL), University of Frankfurt; ³Dept. of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg; ⁴Dept. of Neurology, University Hospital Freiburg; ⁵Dept. of Pediatric Neurology and Muscle Disorders, University Hospital Freiburg; ⁶Clinic and Policlinic for Pediatrics, Department of General Pediatrics, University Hospital Muenster; ⁷Dept. of Neuropathology, University Hospital Heidelberg; ⁸Clinical Cooperation Unit Neuropathology, German Cancer Research Center Heidelberg; ⁹Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center Heidelberg, Germany

"Oncogenic BRAF fusion constitutes a novel mechanism of MAPK pathway activation in pilocytic astrocytoma"

10.10 - 10.30 Uhr: Kaffeepause

10.30 - 12.05 Uhr: Experimentelle Neuroonkologie Teil IV (4)

Vorsitz: Fleischhack / Erdlenbruch

- Petra Hülper¹, Walther Schulz-Schaeffer², Christian Dullin³, Peter Hoffmann⁵, Jay Harper⁶, Leslie Kurtzberg⁶, Scott Lonning⁶, Wilfried Kugler¹, Max Lakomek¹ and Bernhard Erdlenbruch^{1,4}

¹Dept. of Paediatrics I, University of Goettingen, Germany; ²Dept. of Neuropathology, University of Goettingen, Germany; ³Dept. of Diagnostic Radiology, University of Goettingen, Germany; ⁴Johannes Wesling Klinikum Minden, Kinderklinik, Minden, Germany; ⁵Genzyme Corporation, Cambridge, MA, USA; ⁶Cancer and Immunotherapy Research, Genzyme Corporation, Framingham, MA, USA

"Effect of Anti TGF- β antibody treatment on glioblastomas"

- Sandra Jacobs, An Billiau, Catherine Verfaillie, Jef Pinxteren, Stefaan Van Gool
University Hospital Leuven, Belgium

"Immunogenicity and immune modulation by human stem cells"

- Stefaan Van Gool, Hilko Ardon, Wim Maes, Tina Verschuere, Lien Vandenberk, Steven De Vleeschouwer
University Hospital Leuven, Belgium

"Immunotherapy for High Grade Glioma: preclinical research and perspectives"

- Till Milde¹, Susanne Kleber², Andrey Korshunov^{3,4}, Hendrik Witt⁵, Hans-Georg Kopp⁶, Manfred Jugold⁷, Hedwig Deubzer^{1,8}, Ina Oehme¹, Marco Lodrini^{1,8}, Andreas von Deimling^{3,4}, Stefan Pfister^{5,8}, Ana Martin-Villalba², Olaf Witt^{1,8}

¹Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg; ²Dept. of Molecular Neurobiology (G381), German Cancer Research Center, Heidelberg; ³Dept. of Neuropathology, University Hospital Heidelberg; ⁴Clinical Cooperation Unit Neuropathology (G380), German Cancer Research Center, Heidelberg; ⁵Division Molecular Genetics (B060), German Cancer Research Center, Heidelberg; ⁶Dept. of Hematology/Oncology, University Hospital Tübingen; ⁷Project Group Small Animal Imaging, Division of Medical Physics in Radiology (E020), German Cancer Research Center, Heidelberg; ⁸Dept. of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Germany

"Establishment of a novel ependymoma cell line DKFZ-EP1NS with stem cell-like properties"

12.05 - 12.20 Uhr: Kaffeepause

12.20 - 14.00 Uhr: Experimentelle Neuroonkologie Teil IV (4)

Vorsitz: Hernaiz-Driever / Lakomek

- Stefaan Van Gool, Hilko Ardon, Steven De Vleeschouwer
University Hospital Leuven, Belgium

"Immunotherapy for High Grade Glioma: an update of the clinical practice"

- ¹Institute of Toxicology, University Medical Center Mainz, Germany; ²Dept. of Neurosurgery, University Medical Center Mainz, Germany; ³Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, ⁴Dept. of Neuropathology, University Medical Center Mainz, Germany

- E. Koustenis¹, P. Hernáiz Driever¹, G. Henze¹, L. De Sonnevile², SM Rueckriegel¹

“Deficits in planning, attention and information processing in pediatric posterior fossa tumor survivors”

- University Children's Hospital Rostock, Rembrandtstr.16/17, D-18057 Rostock, Germany

“Expression of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) in low-passage patient derived brain tumor cell lines”

14.00 Uhr: Ende der Veranstaltung
anschließend Imbiss

Allgemeine Hinweise

Tagungsort:

Hotel Holiday Inn, Lindenstr. 52, 32423 Minden

Tagungssekretariat:

Johannes Wesling Klinikum Minden, Kinderklinik, Hans-Nolte-Str. 1, 32429 Minden,
Frau Böhlefeld, Frau Thies.

Tel: 0571 790 54001, Fax: 0571 790 294000, e-mail: kinderlinik-mi@klinikum-minden.de

Anmeldeschluss: 25. April 2010

Bitte beiliegendes Anmeldeformular ausfüllen und an das Tagungsbüro per Post, fax oder e-mail zurücksenden.

Tagungsbeitrag:

Tagungspauschale incl. Übernachtung mit Frühstück, Verpflegung während der Tagung, Imbiss am Freitag und Samstag und gemeinsames Abendessen 140,-- Euro

Sonderkonto Bernhard Erdlenbruch, Kto-Nr: 340 871 771, Sparkasse Minden-Lübbecke, BLZ: 490 501 01, bitte Namen und Stichwort „Experimentelle Neuroonkologie“ angeben.

Unterbringung:

Im Rahmen der Tagungspauschale sind alle Teilnehmer im Hotel Holiday Inn, Lindenstrasse 52, 32423 Minden, Tel: 0571 87060 untergebracht. Am Abend des 30.4. wird ein gemeinsames Abendessen als geschlossene Veranstaltung im Hotel Holiday Inn stattfinden.

Vorträge:

Da auch ausländische Wissenschaftler teilnehmen, sollen die Beiträge - wie bereits die Abstracts - wenn möglich in englischer Sprache gehalten werden!

Vortragszeit 25 Minuten inklusive Diskussion.

Wegen der zahlreichen Beiträge bitte ich bereits im Vorfeld darum, die Vortragslänge kurz genug zu konzipieren, damit für eine Diskussion ausreichend Zeit bleibt.

Rückfragen bitte an **PD Dr. Bernhard Erdlenbruch**, Klinik für Kinder- und Jugendmedizin, Klinikum Minden, Hans-Nolte-Str. 1, 32429 Minden;
email: bernhard.erdlenbruch@klinikum-minden.de

Mit freundlicher Unterstützung der Firmen: Biotest AG, Chugai Pharma, Essex Pharma GmbH, Mundipharma, Pfizer Pharma GmbH

Anmeldung zur 19. Arbeitstagung „Experimentelle Neuroonkologie“

Name: _____

Institut: _____

Adresse: _____

Telefon: _____

e-mail: _____

Überweisung von 140,--€ bereits erledigt

☐ (ja)


An der **Kurzbesichtigung Kinderklinik und Neubau Johannes Wesling Klinikum Minden** (12⁰⁰ h bis 13⁰⁰ h) möchte ich teilnehmen

☐ (ja)

Anmeldung bitte an

PD Dr. Bernhard Erdlenbruch,
Kinderklinik Minden, Johannes Wesling Klinikum, Hans-Nolte-Str. 1, 32429 Minden
fax: 0571 790 294000
e-mail: bernhard.erdlenbruch@klinikum-minden.de

Anreise:



Hotel Holiday Inn, Lindenstrasse 52



Kinderklinik